Autonomous Cortisol Secretion Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Autonomous Cortisol Secretion clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Not Applicable

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

Mild Autonomous Cortisol Secretion (MACS)Autonomous Cortisol Secretion (ACS)Subclinical Cushing's+1 more
University of Texas Southwestern Medical Center75 enrolled1 locationNCT07361874
Recruiting
Phase 4

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

Mild Autonomous Cortisol Secretion (MACS)
Johns Hopkins University10 enrolled1 locationNCT07247058
Recruiting
Phase 2

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Mild Autonomous Cortisol SecretionAutonomous Cortisol Secretion (ACS)
Mayo Clinic15 enrolled1 locationNCT07104812
Recruiting
Not Applicable

68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Diagnosing Unilateral Subtype of Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion (PREDICT)

Primary AldosteronismAutonomous Cortisol Secretion
Qifu Li178 enrolled1 locationNCT06833437
Recruiting

Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma

Mild Autonomous Cortisol Secretion (MACS)
The Cleveland Clinic20 enrolled1 locationNCT06344143
Recruiting
Phase 4

Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)

Mild Autonomous Cortisol Secretion (MACS)
Laikο General Hospital, Athens150 enrolled1 locationNCT07268222
Recruiting

Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion

Primary AldosteronismAdrenal InsufficiencyAutonomous Cortisol Secretion
Qifu Li200 enrolled1 locationNCT06955286
Recruiting

Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion

Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
Qifu Li97 enrolled1 locationNCT06635993
Recruiting

Performances on Cognitive Functions and Brain Function and Follow-up After Different Treatments in Patients With Autonomous Cortisol Secretion: a Single-center, Prospective, Observational Study

Adrenal IncidentalomaAutonomous Cortisol SecretionNon-functioning Adrenal Adenomas
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School62 enrolled1 locationNCT05357456